Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19-specific cytotoxic T lymphocytes
- Development stage
- Phase 1
- Lead developer
- Tevogen Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
COVID-19-specific cytotoxic T lymphocytes (CTLs) are an investigational allogeneic cell therapy developed by Thomas Jefferson University for the treatment of elderly and high-risk patients with active COVID-19 infection. This 'off-the-shelf' therapeutic approach utilizes T cells harvested from healthy volunteer donors who have previously recovered from COVID-19. These donor T cells are expanded and manufactured to specifically recognize SARS-CoV-2 antigens. When administered intravenously, these third-party CTLs are intended to provide immediate cellular immunity by identifying and lysing virus-infected cells, thereby reducing viral load and preventing severe disease progression in patients who may be unable to mount an effective natural immune response.
- Other names
- Third-Party COVID-19-Specific Cytotoxic T LymphocytesCOVID-19-specific CTLsCOVID19-specific CTLsCOVID 19-specific CTLsCOVID-19-specific T cellsCOVID19-specific T cellsCOVID 19-specific T cells
02
Targets
SARS-CoV-2 peptide–Major Histocompatibility Complex
Beyond the preview
Go deeper on COVID-19-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19-specific cytotoxic T lymphocytes.